XML 138 R106.htm IDEA: XBRL DOCUMENT v2.4.0.6
EARNINGS PER SHARE (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
EARNINGS PER SHARE      
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $ 159,559 $ (208,193) $ 176,455
Basic weighted-average number of common shares outstanding (000s) (in shares) 304,655 195,808 158,236
Dilutive effect of stock options and RSUs (000s) (in shares) 8,484   274
Dilutive effect of convertible notes (000s) (in shares) 12,980    
Diluted weighted-average number of common shares outstanding (000s) (in shares) 326,119 195,808 158,510
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.      
Basic earnings (loss) per share (in dollars per share) $ 0.52 $ (1.06) $ 1.11
Diluted earnings (loss) per share (in dollars per share) $ 0.49 $ (1.06) $ 1.11